Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

Article  PubMed  Google Scholar 

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E. Early breast cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30:1194–220.

Article  CAS  PubMed  Google Scholar 

Group EBCTC. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27–39.

Article  Google Scholar 

Heater NK, Somayaji K, Gradishar W. Treatment of residual disease following neoadjuvant therapy in breast cancer. J Surg Oncol. 2024;129:18–25.

Article  CAS  PubMed  Google Scholar 

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.

Article  PubMed  Google Scholar 

Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, Bermejo B, Escriva-de-Romani S, Calvo Martínez L, Ribelles N, et al. Optimal [(18)F]FDG PET/CT cutoff for pathologic complete response in HER2-positive early breast cancer patients treated with neoadjuvant trastuzumab and pertuzumab in the PHERGain trial. J Nucl Med. 2024;65:708–13.

Article  PubMed  Google Scholar 

Hwang JP, Choi JY, Choi JH, Cho YS, Hur SM, Kim Z, Lim CW, Seo S, Moon JE, Woo SK, et al. Prognostic value of axillary lymph node texture parameters measured by pretreatment (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer with neoadjuvant chemotherapy. Diagnostics (Basel). 2022;12:2285.

Article  CAS  PubMed  Google Scholar 

Najid S, Seban RD, Champion L, De Moura A, Sebbag C, Salaün H, Cabel L, Bonneau C. Clinical utility of pre-therapeutic [18F]FDG PET/CT imaging for predicting outcomes in breast cancer. J Clin Med. 2023;12:5487.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ulaner GA, Vaz SC. Women’s Health Update: growing role of PET for patients with breast cancer. Semin Nucl Med. 2024;54:247–55.

Article  PubMed  Google Scholar 

Dayes IS, Metser U, Hodgson N, Parpia S, Eisen AF, George R, Blanchette P, Cil TD, Arnaout A, Chan A, et al. Impact of (18)F-labeled fluorodeoxyglucose positron emission tomography-computed tomography versus conventional staging in patients with locally advanced breast cancer. J Clin Oncol. 2023;41:3909–16.

Article  CAS  PubMed  Google Scholar 

Champion L, Lerebours F, Alberini JL, Fourme E, Gontier E, Bertrand F, Wartski M. 18F-FDG PET/CT to predict response to neoadjuvant chemotherapy and prognosis in inflammatory breast cancer. J Nucl Med. 2015;56:1315–21.

Article  CAS  PubMed  Google Scholar 

Quartuccio N, Alongi P, Urso L, Ortolan N, Borgia F, Bartolomei M, Arnone G, Evangelista L. (18)F-FDG PET-derived volume-based parameters to predict disease-free survival in patients with grade III breast cancer of different molecular subtypes candidates to neoadjuvant chemotherapy. Cancers (Basel). 2023;15:2715.

Article  CAS  PubMed  Google Scholar 

Jiménez-Sánchez J, Bosque JJ, Jiménez Londoño GA, Molina-García D, Martínez Á, Pérez-Beteta J, Ortega-Sabater C, Honguero Martínez AF, García Vicente AM, Calvo GF, et al. Evolutionary dynamics at the tumor edge reveal metabolic imaging biomarkers. Proc Natl Acad Sci U S A. 2021;118:e2018110118.

Article  PubMed  PubMed Central  Google Scholar 

Hovhannisyan-Baghdasarian N, Luporsi M, Captier N, Nioche C, Cuplov V, Woff E, Hegarat N, Livartowski A, Girard N, Buvat I, et al. Promising candidate prognostic biomarkers in [(18)F]FDG PET images: evaluation in independent cohorts of non-small cell lung cancer patients. J Nucl Med. 2024;65:635–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, Pellot-Barakat C, Soussan M, Frouin F, Buvat I. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786–9.

Article  CAS  PubMed  Google Scholar 

Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C, Kirsch CM. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46:1342–8.

PubMed  Google Scholar 

Lee JW, Ahn H, Yoo ID, Hong SP, Baek MJ, Kang DH, Lee SM. Relationship of FDG PET/CT imaging features with tumor immune microenvironment and prognosis in colorectal cancer: a retrospective study. Cancer Imaging. 2024;24:53.

Article  PubMed  PubMed Central  Google Scholar 

Waclaw B, Bozic I, Pittman ME, Hruban RH, Vogelstein B, Nowak MA. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature. 2015;525:261–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sprouffske K, Kerr G, Li C, Prahallad A, Rebmann R, Waehle V, Naumann U, Bitter H, Jensen MR, Hofmann F, et al. Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models. Comput Struct Biotechnol J. 2020;18:323–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiménez Londoño GA, García Vicente AM, Bosque JJ, Amo-Salas M, Pérez-Beteta J, Honguero-Martinez AF, Pérez-García VM. Soriano Castrejón Á M: SUVmax to tumor perimeter distance: a robust radiomics prognostic biomarker in resectable non-small cell lung cancer patients. Eur Radiol. 2022;32:3889–902.

Article  PubMed  Google Scholar 

Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel). 2021;13:4455.

Article  CAS  PubMed  Google Scholar 

Sakaguchi R, Kataoka M, Kanao S, Miyake KK, Nakamoto Y, Sugie T, Toi M, Mikami Y, Togashi K. Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer. Ann Nucl Med. 2019;33:570–8.

Article  PubMed  Google Scholar 

Jung YY, Hyun CL, Jin MS, Park IA, Chung YR, Shim B, Lee KH, Ryu HS. Histomorphological factors predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer. J Breast Cancer. 2016;19:261–7.

Article  PubMed  PubMed Central  Google Scholar 

Goktas Aydin S, Bilici A, Olmez OF, Oven BB, Acikgoz O, Cakir T, Basim P, Cakir A, Kutlu Y, Hamdard J. The role of 18F-FDG PET/CT in predicting the neoadjuvant treatment response in patients with locally advanced breast cancer. Breast Care (Basel). 2022;17:470–9.

Article  PubMed  Google Scholar 

Ning L, Xie N. SIRT3 expression predicts overall survival and neoadjuvant chemosensitivity in triple-negative breast cancer. Cancer Manag Res. 2024;16:137–50.

Article  PubMed  PubMed Central  Google Scholar 

Lee IH, Lee SJ, Lee J, Jung JH, Park HY, Jeong SY, Lee SW, Chae YS. Utility of (18)F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer. 2020;20:1106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li P, Wang X, Xu C, Liu C, Zheng C, Fulham MJ, Feng D, Wang L, Song S, Huang G. (18)F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:1116–26.

Article  CAS  PubMed  Google Scholar 

Sengoz T, Arman Karakaya Y, Gültekin A, Yilmaz S, Erdem E, Yapar Taskoylu B, Kesen Z, Yaylali O, Yuksel D. Role of F-18 FDG PET/CT in predicting response to neoadjuvant chemotherapy in invasive ductal breast cancer. Eur J Breast Health. 2023;19:159–65.

Article  PubMed  PubMed Central  Google Scholar 

Oliveira C, Oliveira F, Vaz SC, Marques HP, Cardoso F. Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer. Br J Radiol. 2023;96:20220655.

Article  PubMed  PubMed Central